1h Free Analyst Time
Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H2 2019Speak directly to the analyst to clarify any post sales queries you may have.
Summary
According to the recently published report 'Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H2 2019'; Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Tumor necrosis factor receptor 1 (TNFR1) is a ubiquitous membrane receptor that binds tumor necrosis factor-alpha (TNFalpha). This receptor activates NF-kappaB, mediate apoptosis and function as a regulator of inflammation. Mutations in this receptor were found to be associated with tumor necrosis factor associated periodic syndrome (TRAPS).
The report 'Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H2 2019' outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 2, 4 and 3 respectively.
Similarly, the universities portfolio in Phase I stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Central Nervous System, Gastrointestinal, Immunology, Undisclosed, Infectious Disease and Ophthalmology which include indications Atopic Dermatitis (Atopic Eczema), Multiple Sclerosis, Non-Alcoholic Steatohepatitis (NASH), Soft Tissue Sarcoma, Unspecified, Actinic (Solar) Keratosis, Alzheimer's Disease, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Colon Cancer, Gastrointestinal Tract Cancer, Genital Warts (Condylomata Acuminata), Glioma, Inflammation, Intermediate Uveitis, Kidney Cancer (Renal Cell Cancer), Liver Fibrosis, Melanoma, Metastatic Melanoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Endocrine Tumor, Posterior Uveitis, Prostate Cancer, Psoriasis, Retinitis Pigmentosa (Retinitis), Rheumatoid Arthritis, Solid Tumor, Thyroid Cancer and Warts.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
IntroductionReport Coverage
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Companies Involved in Therapeutics Development
CytImmune Sciences Inc
Eyevensys SAS
G&E Corp
Hillstream BioPharma Inc
Inflamalps SA
Inmune Bio Inc
Philogen SpA
Promethera Biosciences SA
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Drug Profiles
Atrosab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Atrosab (improved formulation) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Atrosimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CYT-21625 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
daromun - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize TNFRSF1A for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EYS-606 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fibromun - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Antagonize TNFRSF1A for Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HSB-114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INB-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Discontinued Products
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Product Development Milestones
Featured News & Press Releases
Aug 05, 2019: INmune Bio reports positive preliminary data from INB03 phase I clinical trial in cancer
Jul 03, 2019: Inmune Bio co-founder and CEO presents at Maxim group's conference on Alzheimer's disease
Jun 04, 2019: INmune Bio to present Alzheimers Drug Candidate XPro1595 at The TNF Conference
Apr 17, 2019: INmune Bio presenting poster at the Neuroimmunology Drug Development Summit
Apr 09, 2019: INmune Bio Co-Founder and CEO to Speak at Cambridge Healthtech Institute's 10th Annual Inflammation Inhibitors Conference
Apr 08, 2019: INmune Bio announces poster presentation with new data regarding neurodegenerative disease drug candidate, XPro1595, at The European Conference on Neuroinflammation
Mar 19, 2019: INmune Bio co-founder and CEO presented at Cambridge Healthtech Institute’s 4th Annual Immuno-Oncology Summit Europe 2019
Feb 11, 2019: INmune Bio awarded a $1 million grant for the development of XPro1595 for the treatment of Alzheimers Disease
Dec 11, 2018: Study results presented at San Antonio Breast Cancer Symposium 2018
Nov 15, 2018: Data from University of Pittsburgh on INB03 for Treatment of Melanoma Presented at the 33rd Annual Society for Immunotherapy of Cancer (SITC) Meeting
Aug 09, 2018: Eyevensys appoints new Board member, Gerald Cagle
Jul 18, 2018: Philogen receives orphan drug designation for the treatment of melanoma
May 23, 2018: INmune Bio Initiates Phase I Clinical Trial of INB03
Mar 12, 2018: Nanotechnology Delivers a Two-Punch Combination With Big Potential for Patients With Rare Cancers
Oct 12, 2017: Philogen Announces Authorization from FDA of a Pivotal Registration Trial in USA for the Treatment of Resectable Melanoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by CytImmune Sciences Inc, H2 2019
Pipeline by Eyevensys SAS, H2 2019
Pipeline by G&E Corp, H2 2019
Pipeline by Hillstream BioPharma Inc, H2 2019
Pipeline by Inflamalps SA, H2 2019
Pipeline by Inmune Bio Inc, H2 2019
Pipeline by Philogen SpA, H2 2019
Pipeline by Promethera Biosciences SA, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019
List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- CytImmune Sciences Inc
- Eyevensys SAS
- G&E Corp
- Hillstream BioPharma Inc
- Inflamalps SA
- Inmune Bio Inc
- Philogen SpA
- Promethera Biosciences SA
